Date: 2016-01-11
Type of information: Establishment of a new subsidiary in the EU
Compound: Roslin Cell Therapies, Roslin Cell Sciences
Company: Roslin Cells (UK)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary in Europe
Action mechanism:
Disease:
Details:
- • On January 11, 2016, Roslin Cells, the Edinburgh and Cambridge based spin out from the Roslin Institute, announced that it has established two subsidiary companies to accelerate the expansion of its commercial operations.
- - Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials. Roslin Cell Therapies builds on the wealth of expertise and industry recognition developed by Roslin Cells in the process development and manufacture of Cell Therapies and Advanced Therapy Medicinal Products (ATMPs). Based at Edinburgh BioQuarter, where it operates purpose built clean room facilities, the company will continue to provide contract manufacturing services for clinical trial supply.
- -Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery. With facilities in both Edinburgh and Cambridge, UK, the company is capable of creating large numbers of iPS cell lines from cohorts of donors. Creating cell lines in this way will enable researchers to understand better how drug performance varies between individuals due to their genetic variation.
Financial terms:
Latest news:
Is general: Yes
